117490-57-0

Basic information

• Product Name: 4-(benzyloxy)-2-chlorobenzaldehyde
• Synonyms: 4-(benzyloxy)-2-chlorobenzaldehyde;Benzaldehyde, 2-chloro-4-(phenylmethoxy)-
• CAS NO: 117490-57-0
• Molecular Formula: C₁₄H₁₁ClO₂
• Molecular Weight: 246.68894
• Mol File: 117490-57-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(benzyloxy)-2-chlorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-2-chlorobenzaldehyde(117490-57-0)
• EPA Substance Registry System: 4-(benzyloxy)-2-chlorobenzaldehyde(117490-57-0)

Safety Data

• Hazardous Substances Data: 117490-57-0(Hazardous Substances Data)

Usage

General Description

4-(benzyloxy)-2-chlorobenzaldehyde is an organic compound with the chemical formula C14H11ClO2. It is a benzaldehyde derivative that contains a benzyl ether and a chlorobenzene moiety. 4-(benzyloxy)-2-chlorobenzaldehyde is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and organic compounds. It is known to have a strong odor and is a yellow to brown colored liquid at room temperature. 4-(benzyloxy)-2-chlorobenzaldehyde has potential applications in the fields of medicine, agriculture, and organic chemistry due to its unique chemical structure and reactivity.

Upstream product

• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 3336-16-1 2-chloro-4-hydroxybenzonitrile 
• 100-51-6 benzyl alcohol 
• 84194-36-5 2-chloro-4-fluorobenzaldehyde 
• 2420-16-8 4-hydroxy-3-chlorobenzaldehyde 
• 853953-30-7 2-chloro-4-benzyloxybenzonitrile 

Downstream Products

• 117490-58-1 8-benzyloxy-7,8-didemethyl-5-deazariboflavin 
• 67759-10-8 1-[4-(benzyloxy)-2-chlorophenyl]-2-(tert-butylamino)ethanol 
• 58020-43-2 (-)-α-[(tert-Butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol 
• 1048041-45-7 C₄₀H₅₁ClN₂O₇SSi 
• 1048041-27-5 2-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]-N-(1H-tetrazol-5-yl)acetamide 
• 1048041-24-2 N-((11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepin-10-yl)sulfonyl)acetylmethanesulfonamide 
• 1048041-28-6 3-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]propionic acid methyl ester 
• 1048041-26-4 2-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]acetamide 
• 1048041-23-1 C₃₁H₃₁ClN₂O₇S 
• 1048041-25-3 [11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]acetic acid 
• 1048041-29-7 11-(4-benzyloxy-2-chlorophenyl)-6-hydroxy-10-methanesulfonyl-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one 
• 1048041-44-6 C₃₇H₄₇ClN₂O₃Si 
• 178053-33-3 4-chloro-1-methyl-6-(4-nitrophenoxy)-2-indoloylguanidine 
• 178053-29-7 4-chloro-1-methyl-6-(2-nitrophenoxy)-2-indoloylguanidine 

Relevant articles and documents

Synthesis of the β2-Agonist Tulobuterol and Its Metabolite 4-Hydroxytulobuterol

Abstract: Alternative methods have been developed for the synthesis of theβ2-agonist tulobuterol and its metabolite4-hydroxytulobuterol with a similar activity. The proposed procedures utilizeavailable reagents, and the key stage in the synthesis is the formation ofintermediate oxirane according to the Corey–Chaykovsky reaction, followed byopening of the oxirane ring by the action of excess tert-butylamine. In the synthesis of 4-hydroxytulobuterol, thehydroxy group was protected by benzylation, and the protecting group was removedin the final stage by hydrogenation over carbon-supported palladium.

Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing

Excessive scar formation is an aberrant form of wound healing and is an indication of an exaggerated function of fibroblasts and excess accumulation of extracellular matrix during wound healing. Much experimental data suggests that prostaglandin E2 (PGE2) plays a role in the prevention of excessive scarring. However, it has a very short half-live in blood, its oxidization to 15-ketoprostaglandins is catalyzed by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Previously, we reported that 15-PGDH inhibitors significantly increased PGE2 levels in A549 cells. In our continuing attempts to develop highly potent 15-PGDH inhibitors, we newly synthesized various thiazolidine-2,4-dione derivatives. Compound 27, 28, 29, and 30 demonstrated IC50 values of 0.048, 0.020, 0.038 and 0.048 μM, respectively. They also increased levels of PGE2 in A549 cells. Especially, compound 28 significantly increased level of PGE2 at 260 pg/mL, which was approximately fivefold higher than that of control. Scratch wounds were analyzed in confluent monolayers of HaCaT cells. Cells exposed to compound 28 showed significantly improved wound healing with respect to control.

SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME

Provided are a substituted azole derivative and pharmaceutically acceptable salts thereof, a pharmaceutical composition including an effective amount of the derivative, and a method for treating Parkinson's disease in a mammal including administering an e